Get a Comprehensive Overview of the Cardiac Biomarkers Market Report Prepared by P&S Intelligence, Segmented by Type (Troponins, Myocardial Muscle Creatine Kinase, Myoglobin, BNPs, IMA, ALT/AST), Application (Myocardial Infarction, Congestive Heart Failure, Atherosclerosis), Testing Location (Laboratory Testing, Point-of-Care Testing), and Geographic Regions. This Report Provides Insights From 2019 to 2030
Explore the market potential with our data-driven report
Cardiac Biomarkers Market Future Prospects
The global cardiac biomarkers market size is USD 20.8 billion in 2024, and it is expected to generate USD 44.6 billion by 2030, advancing with a robust CAGR of 13.4% during 2025-2030.
The market is driven by the growing rate of acute coronary syndromes (ACS), which are an ongoing challenge for healthcare systems across the world. The technological advancements in cardiac biomarkers, such as high-sensitivity troponin assays, have made early detection and risk stratification easier and reduced diagnostic uncertainties.
Further, the ever-growing usage of point-of-care (POC) testing kits enables faster clinical decision-making in emergency cases, thereby improving patient outcomes. The need for higher specificity and sensitivity in detecting cardiac conditions, especially myocardial infarctions, drives the demand for new biomarker solutions.
The investments put in by government and private institutions in research and development in this area of diagnostics encourage product innovations. The geriatric population is more vulnerable to heart diseases; thus, the demand for sophisticated diagnostic solutions is high. The rising awareness among healthcare professionals and patients of early diagnosis further boosts the growth of the market.
Cardiac Biomarkers Market Trends and Growth Drivers
Usage of AI and ML for Cardiac Biomarker Identification Is Major Trend
The requirement for biomarkers that can better provide information concerning predictive, prognostic, and diagnostic implications is leading to advancements in this sensitive analytical technique.
The integration of artificial intelligence (AI) and machine learning (ML) with diagnostic platforms improves the identification of biomarkers, allowing for personalized therapeutic approaches in cardiology.
AI-driven algorithms can analyze complex data on biomarkers, helping clinicians understand the patterns related to early cardiac events that traditional biomarkers might not detect.
The systems enhance predictive modeling for cardiovascular risk, thereby assisting practitioners diagnose and prognose reliably. For instance, AI-enabled tools better read and interpret troponin levels, CRP, and BNP, thus speeding up the detection of ACS or heart failure.
The incorporation of biomarkers with wearable devices and remote monitoring systems enables faster tracking and monitoring of patient health and minimizes hospital readmissions.
AI-enhanced biomarkers also help in building individualized therapeutic strategies in cardiology with specifically designed interventions based on the unique cardiac profile of each individual. This confirms the best therapeutic outcome, driving the transition toward personalized medicine and improving long-term heart health management.
Furthermore, the integration of PoC kits with AI-based analytics in clinical settings delivers quicker, more-reliable, and better patient outcomes.
Increasing Prevalence of CVDs Boosts Demand for Cardiac Biomarkers
The market for cardiac biomarkers is growing due to the rising prevalence of CVDs. According to the WHO, approximately 17.9 million deaths globally are caused by CVDs each year, which is 32% of all global fatalities. Moreover, the number of deaths from CVDs and strokes is forecast to rise to 23.6 million by 2030.
The increasing prevalence of CVDs is due to the sedentary lifestyles, unhealthy eating habits, rising incidence of obesity, and soaring levels of stress.
This has raised the demand for rapid and specific techniques for the early diagnosis of cardiac disorders and to prevent them from entering the severe stages.
Cardiac biomarkers have emerged as vital tools in detecting heart damage, monitoring disease progression, and tracking the effect of treatment.
Various market players are aiming to offer test kits for the detection of biomarkers that enable a better understanding of the pathogenesis of CVDs.
Major biomarkers include B-type natriuretic peptide (BNP), C-reactive protein, N-terminal prohormone BNP, lipoprotein-associated phospholipase A2, and cystatin C.
The adoption of biomarkers in the diagnosis of ACS and creation of personalized treatment strategies is an essential factor driving the market.
Furthermore, the collaborations among healthcare providers and diagnostics solution companies for bringing new biomarker technologies increase their availability and accessibility.
Limited Specificity of Cardiac Biomarker Hinders Market Growth
The problem with cardiac biomarkers lies in their limited specificity, meaning they can indicate heart damage, but can also detect non-cardiac conditions, including kidney disease, infections, or extreme physical stress. This overlap can lead to false positives or misdiagnoses, creating confusion among clinicians in ascertaining that the elevated levels of the are because of a cardiovascular event. This requires additional diagnostic testing, such as imaging studies or repeat biomarker testing.
Such delays compromise treatment decisions and the outcomes for the patient. This limitation hampers the growth of the cardiac biomarkers market due to the less confidence in its standalone reliability. This makes healthcare providers reluctant to use these tests extensively, particularly in emergencies, due to their risk of misdiagnoses.
Cardiac Biomarkers Market Analysis
Type Analysis
Troponins account for the major revenue share of, over 30%, in 2024 in the market, and this category is expected to grow with a robust CAGR during the forecast period. This is due to the extraordinary specificity and capacity of their protein complex to help accurately recognize cardiac problems, such as ACS. Additionally, the high prevalence of myocardial infarction will drive the market, as troponin is now the most common tool to detect this condition.
B-type natriuretic peptides (BNPs) are the fastest-growing category in the market, due to their significant role in the early diagnosis and management of congestive heart failure (CHF). With the increasing prevalence of CHF all over the world, BNP and NT-proBNP are becoming increasingly used in monitoring disease progression. As per estimates, 6.2 million people in the U.S. have CHF.
Moreover, in April 2024, Roche Diagnostics India launched a POC NT-proBNP test exclusively on the Cobas h 232 system. It allows for the screening of diabetic patients at risk of cardiovascular diseases, including heart failure. This test seeks to enable early detections and timely interventions for high-risk type 2 diabetes patients.
The types evaluated here:
Troponins (Largest Category)
Myocardial Muscle Creatine Kinase
Myoglobin
BNPs (Fastest-Growing Category)
IMA
ALT/AST
Others
Application Analysis
Myocardial infarction is the second highest revenue contributor, with 35% share, in 2024, and this category is further expected to dominate the market during the forecast period. This is due to its rising incidence globally because of the changing lifestyles, unhealthy food, excessive smoking, hypertension, diabetes, hyperlipidemia, family history of obesity, and coronary artery disease.
Because a quick and accurate diagnosis is vital for avoiding fatalities due to acute myocardial infarctions, PoC testing kits, alongside lab-based assays, have become utmost important in emergency departments. Cardiac biomarkers, such as troponins and CK-MB, are the most commonly used for the diagnosis, monitoring, and risk stratification of myocardial infarctions and other acute coronary syndromes.
The fastest-growing category in the cardiac biomarker market is congestive heart failure. The cause most commonly linked to CHF is coronary artery disease, with others including high cholesterol levels and/or triglyceride levels in the blood. In terms of biomarkers, B-type natriuretic peptide and N-terminal prohormone BNP have become significant in diagnosing CHF, monitoring its progression, and estimating prognostic outcomes.
These biomarkers are used to evaluate the severity of heart failure, make treatment-related decisions, and monitor a patient's response to therapy. Furthermore, the surge in the demand for biomarker tests for the early detection of heart failure is the key factor set to boost the cardiac biomarkers market growth in the coming years.
Laboratory testing accounts for the larger revenue share, and this category is expected to maintain its position during 2025–2030. This is due to the increase in healthcare spending and the number of reforms for healthcare infrastructure improvement, rise in the disposable income, and the government and private sectors’ initiatives aimed at preventing heart diseases.
The point-of-care testing category will grow with the higher CAGR, of 15.0%, during the forecast period because doctors are increasingly adopting this approach to monitor patients with chest pain in critical care centers.
The testing locations analyzed here are:
Laboratory Testing (Largest Category)
Point-of-Care Testing (Fastest-Growing Category)
Drive strategic growth with comprehensive market analysis
Regional Analysis
The North American cardiac biomarkers market accounted for the largest revenue share, of over 40%, in 2024. The dominance of the region can be attributed to the increasing usage of biomarkers for precision medicine, different growth strategies implemented by market players, and the increasing adoption of biomarkers for the detection of cardiac diseases.
The U.S. contributes the majority of the revenue to the regional market as it is the base for several market players and accounts for a high R&D expenditure in the healthcare sector.
APAC will be the fastest-growing market for such biomarkers, with a CAGR of around 14.0%, during the forecast period. This can be attributed to the growing healthcare infrastructure, various government schemes for the healthcare sector, high investment by market giants, high prevalence of cardiac diseases, and rising aging population.
China holds the largest regional cardiac biomarkers market share, and it will witness significant growth in the coming years. The high morbidity and mortality due to CVDs, the government’s Healthy China 2030 plan, and the availability of advanced imaging, coronary stenting, and other technologies will boost the market growth in the country.
India is the most significant contributor to the market, following China, in the region. This is due to the rising cases of heart failure in adults because of the evolving lifestyles, improvements in specialized treatment approaches, and government schemes supporting the healthcare sector.
In addition, Europe holds a significant revenue share in the global market due to the presence of prominent research institutions and market players. Furthermore, the industry growth can be ascribed to the rising number of collaborations between regional universities and biomarker providers, governments and market players’ R&D initiatives related to biomarkers, and the strong efforts being taken to create awareness about the benefits of biomarkers.
The geographical breakdown of the market is as follows:
The cardiac biomarker market is consolidated in nature due to the presence of a few key players that hold large market shares. This results from the stringent clinical protocols and regulatory approvals, as biomarker tests need to meet the requisite standards of accuracy, reliability, and safety. Huge investments are required for research and development, thus giving an advantage to the big and established corporations that have access to the latest technologies and resources. Furthermore, strategic partnerships and collaborations with healthcare professionals and clinical settings solidify the position of the top firms.
Key Providers of Cardiac Biomarker Testing Solutions:
Abbott Laboratories
F. Hoffmann-La Roche Ltd.
bioMérieux Inc.
Creative Diagnostics
Thermo Fisher Scientific Inc.
Bio-Rad Laboratories Inc.
Siemens Healthineers AG
Randox Laboratories Ltd.
Shenzhen Mindray Bio-Medical Electronics Co. Ltd.
Danaher Corporation
Agilent Technologies Inc.
Becton, Dickinson and Company
Cardiac Biomarkers Market News
In June 2024, Siemens Healthineers improved its Atellica Solution cardiac testing capabilities with the introduction of the NT-proBNPII assay, which helps in the enhanced detection of heart failure. Both N-terminal pro-BNP and B-type natriuretic peptides are vital markers released because of an increase in ventricular filling pressure. The NT-proBNPII assay delivers results within 10 minutes, thereby allowing for timely patient care, and it can be performed on the Atellica IM or CI analyzer.
In October 2023, Shenzhen Mindray Bio-Medical Electronics Co. Ltd. expanded its cardiac biomarker portfolio with the addition of high-sensitivity troponin I and NT-proBNP assays. These biomarkers are critical for facilitating the early screening, risk stratification, and rapid diagnosis of acute coronary syndromes and heart failure. The hs-cTnI assay boasts a detection rate of 93%, with minimal imprecision of 5%.
Frequently Asked Questions About This Report
What is the value of the cardiac biomarkers market in 2024?+
The value of the market for cardiac biomarkers is USD 20.8 billion in 2024.
Which is the dominant application in the cardiac biomarkers industry?+
Myocardial infarction dominates the cardiac biomarkers industry.
What are the key drivers for the cardiac biomarkers market?+
The market for cardiac biomarkers is driven by the rising geriatric population, increasing incidence of CVDs, and surging awareness of the utility of biomarkers.
What is the regional scenario of the cardiac biomarkers industry?+
North America is the largest region, while Asia-Pacific is the fastest-growing region in the cardiac biomarkers industry.
What is the cardiac biomarkers market competitive nature?+
The market for cardiac biomarkers is consolidated.
Leading companies across industries trust us to deliver data-driven insights and innovative solutions for their most critical decisions. From data-driven strategies to actionable insights, we empower the decision-makers who shape industries and define the future. From Fortune 500 companies to innovative startups, we are proud to partner with organisations that drive progress in their industries.
Client Testimonials
Working with P&S Intelligence and their team was an absolute pleasure – their awareness of timelines and commitment to value greatly contributed to our project's success. Eagerly anticipating future collaborations.
McKinsey & Company
India
Unmatched Standards
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
Complete Data Security
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws